Scarica l'app Stockscreener
3.135
1.72%
-0.055
Dopo l'orario di chiusura:
3.14
0.005
+0.16%
Ac Immune Sa Borsa (ACIU) Ultime notizie
HC Wainwright Reaffirms “Buy” Rating for AC Immune (NASDAQ:ACIU) - Defense World
AC Immune’s stock jumps after Parkinson’s therapy shows signs of benefit - Clinical Trials Arena
AC Immune (NASDAQ:ACIU) Given "Buy" Rating at HC Wainwright - MarketBeat
AC Immune reports interim results from Phase 2 trial of ACI-7104.056 - Yahoo Finance
AC Immune (ACIU) Sees Stock Boost Following Positive Trial Data - Stocks Telegraph
Short Interest in AC Immune SA (NASDAQ:ACIU) Increases By 23.5% - MarketBeat
AC Immune SA (NASDAQ:ACIU) Short Interest Up 23.5% in October - Defense World
AC Immune stock jumps 20% on data for Parkinson's disease drug (NASDAQ:ACIU) - Seeking Alpha
S&P 500 Moves Lower; US Crude Oil Inventories Increase - Benzinga
AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients - Benzinga
AC Immune Phase II ACI-7104.056 success in Parkinson’s - The Pharma Letter
AC Immune's Parkinson's vaccine shows promise in early trial - Investing.com India
AC immune announces positive trial results for early Parkinson’s treatment - PharmaTimes
AC Immune’s Promising Trial Results for Parkinson’s Therapy - TipRanks
Immunotherapy in Early Parkinson’s Disease Posts Positive Interim Results from Phase 2 Study - Precision Vaccinations
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease - The Manila Times
AC Immune's Parkinson's vaccine shows promise in early trial By Investing.com - Investing.com UK
AC Immune's Parkinson's Drug Shows 16x Higher Antibody Levels in Phase 2 Trial | ACIU Stock News - StockTitan
AC Immune to Present at the Jefferies 2024 London Healthcare Conference - Yahoo Finance
Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights - The Manila Times
Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board - The Manila Times
AC Immune SA Beat Analyst Profit Forecasts, And Analysts Have New Estimates - Yahoo Finance
Leerink Partnrs Increases Earnings Estimates for AC Immune - Defense World
FY2024 EPS Estimates for AC Immune Lifted by Leerink Partnrs - MarketBeat
FY2024 EPS Estimates for AC Immune Boosted by HC Wainwright - MarketBeat
HC Wainwright Reaffirms Buy Rating for AC Immune (NASDAQ:ACIU) - Defense World
Brokers Set Expectations for AC Immune FY2027 Earnings - MarketBeat
HC Wainwright Reiterates "Buy" Rating for AC Immune (NASDAQ:ACIU) - MarketBeat
AC Immune: Q3 Earnings Snapshot - San Francisco Chronicle
AC Immune reports Q3 EPS CHF 0.05 vs (CHF 0.18) last year - TipRanks
AC Immune SA Reports Profitable Q3 2024 Results - TipRanks
AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update - The Manila Times
Will ABATE Trial Data Lift AC Immune's Stock Price? - RTTNews
Assenagon Asset Management S.A. Has $846,000 Stock Position in AC Immune SA (NASDAQ:ACIU) - MarketBeat
Short Interest in AC Immune SA (NASDAQ:ACIU) Decreases By 7.4% - MarketBeat
AC Immune SA (NASDAQ:ACIU) stock most popular amongst individual investors who own 32%, while private equity firms hold 29% - Yahoo Finance
What To Expect From AC Immune SA (ACIU) Q3 2024 Earnings - Yahoo Finance
Roche leaves Alzheimer partnership with UCB - European Biotechnology News
UCB Assessing Bepranemab’s Future After Roche/Genentech Ends Partnership - Citeline
Scrip Asks…What Does 2023 Hold For Biopharma? Part 5: Technological Advances - Citeline News & Insights
AC Immune SA (NASDAQ:ACIU) Sees Significant Increase in Short Interest - MarketBeat
AC Immune SA (NASDAQ:ACIU) Short Interest Up 12.9% in September - MarketBeat
AC Immune (NASDAQ:ACIU investor three-year losses grow to 47% as the stock sheds US$40m this past week - Simply Wall St
Renaissance Technologies LLC Has $2.60 Million Position in AC Immune SA (NASDAQ:ACIU) - MarketBeat
AC Immune (NASDAQ:ACIU) Downgraded by StockNews.com - Defense World
AC Immune (NASDAQ:ACIU) Downgraded by StockNews.com to Hold - MarketBeat
Down Syndrome Market Forecasted to Surge in Coming Years, 2023-2032 Analysis by DelveInsight | AstraZeneca, Aelis Farma, AC Immune SA, Eisai Inc., Hoffmann-La Roche, Life Molecular Imaging SA - Barchart
CompleCure, AGC Biologics Partner To Develop Advanced Anti-Cancer Therapy - Contract Pharma
CompleCure Partners with AGC Biologics’ Chiba Site to Develop Advanced Anti-Cancer Therapeutic Using Pioneering AMDC Technology - AccessWire
Why Industry Must Design Alzheimer's Trials To Include People With Down Syndrome - Clinical Leader
Investment Analysts’ Upgrades for September 23rd (ACIU, APD, BBY, BLD, CIGI, DQ, EBR, GFF, HBNC, KOPN) - Defense World
AGC Biologics and CompleCure Collaborate on Innovative Breast Cancer Treatment - Vancity Buzz
Bulls beat South and advance to Australia Cup final - MSN
Europe Alzheimers Therapeutics Market Size & Outlook, 2030 - Grand View Research
Australia Alzheimers Therapeutics Market Size & Outlook, 2030 - Grand View Research
AC Immune SA Welcomes New CMO Dr. Anke Post - TipRanks
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):